Pharmagreen Biotech Inc PHBI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHBI is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $431,369.73
- Volume/Avg
- 3.0 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 266.67
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- https://www.pharmagreen.ca
Valuation
|
Metric
|
PHBI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 266.67 |
Price/Cash Flow | — |
Price/Earnings
PHBI
Financial Strength
|
Metric
|
PHBI
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.02 |
Interest Coverage | −4.25 |
Quick Ratio
PHBI
Profitability
|
Metric
|
PHBI
|
|---|---|
Return on Assets (Normalized) | −338.15% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PHBI
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Gstrcgncf | Jfhcbxg | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Xdyqwybjxg | Yhyp | $69.9 Bil | |
HLN
| Haleon PLC ADR | Lwylzrv | Gpl | $36.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Nmvsjddx | Sxmf | $14.9 Bil | |
VTRS
| Viatris Inc | Gnhhgzqvg | Bcpt | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Wkyjhpfg | Wqqbj | $12.1 Bil | |
CTLT
| Catalent Inc | Wsdwkbgtt | Bzjjwx | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Fnpxmdny | Nhmc | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Qczsccjq | Tfz | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xmdnchtz | Jhrgs | $3.4 Bil |